ArticleScientific reports2025
Age disparities in adverse reactions of drugs used in pain therapies in Switzerland.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pain therapies are prescribed to a significant proportion of the population but also associated with adverse drug reactions (ADRs). The prescription of pain therapies requires careful consideration of their safety profiles in the context of patient-specific characteristics, such as age-specific vulnerabilities, which are, however, still understudied so far. The aim of this study was to describe ADRs reported for drugs used in pain therapies and investigate age disparities. We conducted a descriptive comparative analysis of individual case safety reports (ICSRs) of drugs used in pain therapies from the global ADR database VigiBase between September 29, 1991, and December 31, 2022, from Switzerland. Comparisons were drawn between younger and older adults (18-74 years vs. 75 + years). Disproportionality (reporting odds ratio, ROR) of serious ADRs was assessed between age groups. A total of 17,228 ICSRs were analysed (58% female, 24% age 75 +). Across both age groups, the most frequently reported ADRs were related to the nervous system (23%), gastrointestinal system (20%), and general health and administration site conditions (20%). Serious ADRs were more common in the older population compared to younger adults (69% vs. 54%) with an ROR of 1.9. Fatal ADRs were also disproportionally higher in older adults (ROR 1.9). Hemorrhage was the most frequent fatal reaction. Commonly used pain therapies can lead to ADRs with a pronounced impact, especially in older adults. A deeper understanding of the safety profiles of these drugs should aid healthcare professionals in making more informed, safer treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.